Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Deprexil in Subjects With Signs and Symptoms of Depression

This study has been completed.
Sponsor:
Information provided by:
Catalysis SL
ClinicalTrials.gov Identifier:
NCT01043367
First received: January 5, 2010
Last updated: March 6, 2011
Last verified: March 2011
  Purpose
The purpose of the study is to assess the efficacy of DEPREXIL administration in combination with relaxation psychotherapy in the treatment of patients with signs and symptoms of depression. The duration of this double-blind placebo controlled phase 3 clinical trial will be 24 weeks. The estimated number of persons to be recruited and randomized for the study is 200.

Condition Intervention Phase
Depression
Dietary Supplement: Deprexil
Dietary Supplement: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy of Deprexil Administration in Subjects With Signs and Symptoms of Depression.

Further study details as provided by Catalysis SL:

Primary Outcome Measures:
  • Functional capabilities at week 24 (end of the treatment) [ Time Frame: 24 weeks ]
  • Social capabilities at week 24 (end of the treatment) [ Time Frame: 24 weeks ]
  • Psycho-affective capabilities at week 24 (end of the treatment) [ Time Frame: 24 weeks ]
  • Behavioral capabilities at week 24 (end of the treatment) [ Time Frame: 24 weeks ]

Secondary Outcome Measures:
  • Tolerability to Deprexil at week 24 (end of the treatment) [ Time Frame: 24 weeks ]
  • Symptoms of depression at week 24 (end of the treatment) [ Time Frame: 24 weeks ]
  • Signs of depression at week 24 (end of the treatment) [ Time Frame: 24 weeks ]
  • Clinical symptoms of baseline disease at 24 weeks (end of the treatment) [ Time Frame: 24 weeks ]

Estimated Enrollment: 200
Study Start Date: January 2010
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Deprexil
Dietary Supplement: Deprexil
One 600 mg Deprexil tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
Placebo Comparator: B
Placebo
Dietary Supplement: Placebo
One Placebo tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.

  Eligibility

Ages Eligible for Study:   18 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Mild or moderate symptoms and signs of depression for more than 3 months and less than 3 years of duration.
  • Signed informed consent

Exclusion Criteria:

  • Severe symptoms and signs of depression or Suicide proneness.
  • Pregnancy or breastfeeding
  • Receiving other experimental drug
  • Use of anti-depressive medication within 15 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01043367

Locations
Cuba
"Heroes del Moncada" Polyclinic
Havana City, Havana, Cuba, 10400
Sponsors and Collaborators
Catalysis SL
Investigators
Principal Investigator: Maria de la Concepción Valdivia Alarcón, MD "Heroes del Moncada" Polyclinic
  More Information

Responsible Party: Maria de la Concepción Valdivia Alarcón, "Heroes del Moncada" Polyclinic
ClinicalTrials.gov Identifier: NCT01043367     History of Changes
Other Study ID Numbers: CAT-0908-CU
Study First Received: January 5, 2010
Last Updated: March 6, 2011

Keywords provided by Catalysis SL:
Depression
Dietary supplement
Deprexil

Additional relevant MeSH terms:
Depression
Depressive Disorder
Signs and Symptoms
Behavioral Symptoms
Mood Disorders
Mental Disorders

ClinicalTrials.gov processed this record on May 22, 2017